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Abstract Background Recombinant (rec-) coagulation factor VIII concentrates available for
hemophilia A (HA) treatment differ in cell line production and structure, which could
affect their pharmacodynamics and immunogenicity. Clinical trials showed that
previously untreated patients with severe HA present higher rates of inhibitor devel-
opment if treated with rec-FVIII products and that differences do exist as to inhibitor’s
formation among different rec-FVIII products. This finding could arise from several
causes, such as absence of von Willebrand factor, different glycosylation profiles, or
processes of molecular aggregation of the recombinant FVIII molecules.
Objectives/Methods In this study, using size exclusion high-performance liquid
chromatography (SE-HPLC), dynamic light scattering (DLS) spectroscopy, and func-
tional biochemical assays, we investigated the purity grade, FX activating ability, and
aggregation status of three recombinant marketed products (Advate [Baxalta], Refacto
AF [Pfizer], and Kogenate [Bayer]).
Results The overall analysis of the results obtained with SE-HPLC and DLS spectro-
scopy showed that the three recombinant FVIII concentrates contain low but significant
amounts of molecular aggregates. This phenomenon was less evident for the Advate
product. Molecular aggregation negatively affects the in vitro pharmacodynamics of
the concentrates with higher aggregates’ content.
Conclusions This study shows that the three pharmaceutical formulations of recom-
binant FVIII contain variable amounts of molecular aggregates after their reconstitu-
tion at therapeutic concentrations. This phenomenon negatively affects the in vitro
potency of the products with higher aggregates’ content and might be invoked as a
contributing cause of their increased risk to induce the formation of FVIII inhibitors.
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Introduction
Patients with hemophilia A are currently treated with FVIII
concentrates preparedwith both recombinant technology and
fractionation/purification from plasma of healthy donors.
Recombinant FVIII products are produced by different cell
lines, which synthesize FVIII molecules with the same primary
sequence of the human factor (except the B-deleted and B-
truncated molecules). However, these recombinant molecules
inevitably go through different posttranslational modifica-
tions, such as glycosylation and tyrosine sulfation processes.1
Furthermore, the process of expression and purification of
recombinant FVIII products may potentially cause the accu-
mulation of misfolded and aggregated proteins. These aspects
maybe responsible for perturbationof the efficiencyand safety
(regarding the inhibitor formation) of the recombinant pro-
ducts, as suggested in official documents by regulatory agen-
cies.2 The purification process of recombinant FVIII products
includes a solvent/detergent virus inactivation step in addition
to the use of ion exchange chromatography, and monoclonal
antibody immunoaffinity chromatography to remove contam-
inating substances.3,4Chemical stabilizers such as amino acids,
sugars, andnonionic surfactants areadded for themaintenance
of the structural/functional integrity of recombinant FVIII
products.3 It has been questioned whether the production of
FVIII innonhumancells and themanufacturingprocesses could
induce structural changes in the FVIII molecules and whether
this might be the cause of different properties of products in
terms of immunogenicity. Previous findings from randomized
clinical trials (RCTs) and national hemophilia registries pro-
vided evidence that recombinant FVIII products are associated
with high risk of inhibitor formation and that the
recombinant second-generation FVIII products were asso-
ciated with an even higher risk of inhibitor formation than
the third-generation recombinant products.5–7
In this study, we investigated some biochemical properties
and, using size exclusion high-performance liquid chromato-
graphy (SE-HPLC) and dynamic light scattering (DLS) spectro-
scopy, theaggregationstatusof threerecombinantconcentrates
belonging to the second (Kogenate) and third-generation pro-
ducts (Advate and Refacto AF). We addressed the issue of
whether the molecular aggregation status of these products
in solution after their reconstitution could significantly differ
among products, affect their activity, and be invoked as a
potential cause of inhibitor formation in hemophilia A patients.
Materials and Methods
FVIII Products
Three recombinant products (Advate [Baxalta/Shire], Refacto
AF [Pfizer], and Kogenate [Bayer]) were studied. Three dif-
ferent lots of each product were used. In some experiments,
Recombinate [Baxalta], the first-generation product of
Advate and thus containing albumin, was also studied. FVIII
preparations were reconstituted in distilled water for injec-
tion and passed through the particle filters (5 µm) contained
in the pharmaceutical kit. The samples were immediately
used for the experiments described below.
UV Spectra of Recombinant FVIII Preparations
Ultraviolet (UV) absorbance scans of reconstituted Advate,
Kogenate, and Refacto and genuine polysorbate 80 (TWEEN
80, purchased fromMerck), histidine (25 mM,purchased from
Sigma-Aldrich), and PEG3350 (U.S. Pharmacopeia [USP] Refer-
ence Standard, Sigma-Aldrich) were performed over a 220 to
340 nm wavelength range in a 1-cm-pathlength quartz cell
lodged in a thermostated cell holder of a Cary 60 spectro-
photometer (Agilent Technologies Italia S.p.A. Milano, Italy).
All the products were reconstituted with sterile water for
injection by the use of the kits supplied by the manufacturers
for therapeutic delivery and used at a final concentration of
nominal 3,000 IU/mL (ffi 0.6 mg/mL, considering an activity
of ffi 5,000 IU/mg for the FVIII reference). The approximate
concentrations of the aboveproductsweremeasuredbasedon
the extinction coefficient at 280 nm using ε(01%) ¼ 1.3 for
the full-length FVIII products Advate and Kogenate,8 and
ε(01%) ¼ 1.55 for the B-deleted FVIII Refacto AF.9
SE-HPLC of the Recombinant FVIII Concentrates
FVIII samples of reconstituted Advate, Kogenate, and Refacto
at a final nominal concentration of 400 IU/mL (ffi 80µg/mL)
were analyzed by SE-HPLC using a TSK gel Super SW3000
column coupled to a two-pump apparatus (Jasco Easton,
Maryland, United States), equipped with a spectrophoto-
metric device (model 2075), and a spectrofluorometric
detector (FP-2020, Jasco). The spectrophotometric detection
of the eluted peaks was accomplished at 280 nm, whereas
the fluorescence of the proteins was monitored by using
λex ¼ 280 nm and λem ¼ 340 nm. The elution buffer was a
solution containing 20 mM phosphate buffer, 0.15 M NaCl,
and pH ¼ 7.40. Theflow ratewas 0.4mL/min in all cases, and
the injection volume was 75 µL. The same FVIII preparation
was also filtered through a low-binding protein Millex-GP
220 nm filter (Merck) and analyzed again by SEC-HPLC, as
detailed above.
Dynamic Light Scattering Measurements of FVIII
Concentrates
The outlines of the theory related to DLS techniques are
described in biophysics textbook.10 We shall only briefly
describe the aim of our experimental strategy. In these
experiments we used nominal concentrations of the rec-
FVIII products usually employed for therapeutic infusions,
corresponding to 100 to 250 IU/mL (20–50 µg/mL; 50–
125 nM, considering a m.w. of full-length FVIII 275 kDa).
At these concentrations, verified spectrophotometrically at
280 nm, the different rec-FVIII could not be detected in DLS
spectroscopy. This bias was further complicated by the
presence of a relatively high concentration of the excipients
and stabilizers that actively contributed to the DLS signal.
However, if molecular aggregates of rec-FVIII were present
in solution, getting very high molecular mass, these objects
should be detected in DLS spectra, even at a low concentra-
tion, as the signal’s intensity is proportional to d6 (where,
from Rayleigh approximation, d is the hydrodynamic radius
of a spherical particle). Hence, DLS intensity spectra of the
genuine major excipients/stabilizers present in the various
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preparations (polysorbate 80, histidine, PEG 3350, manni-
tol, and threalose) were separately measured and com-
pared with the DLS spectra obtained with the individual
rec-FVIII products that contained the same stabilizers
at similar concentrations. From this comparison, it was
possible to detect and attribute components in solution
that could be likely assigned to aggregated particles of the
rec-FVIII molecules, as microscopic particulate was elimi-
nated by the filters contained in the pharmaceutical kits.
The DLS measurements were accomplished with a Zetasizer
Nano S instrument (Malvern Instruments Ltd, Worcester-
shire, United Kingdom), equipped with a 4 mW He-Ne laser
(633 nm) at 25°C at an angle of 173 degrees for determining
the hydrodynamic diameter of molecular species in FVIII
preparations.11–13 The following recombinant FVIIIs pow-
dered preparations were used: Refacto AF (Pfizer), Advate
(Baxalta), Recombinate (Baxalta), and Kogenate. The
powders were all reconstituted in sterile water and gently
mixed until completely dissolved. Serial dilutions in
sterile water occurred immediately after resuspension to
analyze each preparation in the range of 100 to 250 IU/mL
(ffi 20–50 µg/mL ffi 50–125 nM) in a 45 μL quartz cuvette of
10 mm light path (Hellma Analytics, Germany). Reported
data were acquired at the therapeutic concentration of
100 to 250 IU/mL and confirmed at different concentrations
(data not shown). The intensity autocorrelation function
(see the legend to►Fig. 4) was analyzed using version 5.0 of
the Zetasizer Nano Software (CONTIN algorithm).11
Cleavage of FVIII by Thrombin: Western Blot Method
The three rec-FVIII preparations (final concentration: 100 IU/
mL, ffi 20 µg/mL ffi 70 nM) were reacted with 2.5 nM human
thrombin (final concentration), purified as previously
detailed,14 in 5 mL of a buffer containing 50 mM Tris (pH
8.0), 150 mMNaCl, 2.5 mMCaCl2, and0.1%2-mercaptoethanol
at 25°C, according to a previous report.11 Proteolysis by
thrombinwasmonitoredbyWesternblottingof theA2domain
(aa 375–719) of FVIII, recognized by the mouse monoclonal
antibody (MoAb) sc-73597 (Santa Cruz Biotechnology, Heidel-
berg, Germany), as detailed below. Reactions were performed
at 25°C for 30 minutes and, in some cases, up to 180 minutes.
Proteinswere electrophoretically transferred (45minutes, 100
V) to a polyvinylidene difluoride membrane in Tris-buffered
saline (TBS) 10X. Blocking was performed overnight at 4°C in
10% (w/v) nonfat dried milk in TBS with 0.1% Tween 20 to
reduce the likelihood of false positives. Incubation was per-
formed with antibodies against the full-length-FVIII (FL-FVIII)
molecule. The anti-FL-FVIII monoclonal antibody sc-59508
(Santa Cruz Biotechnology, Heidelberg, Germany) recognizes
a structural epitope of the entire intact FVIII molecule (native
factor VIII A2 domain of human origin). A different mouse
monoclonal antibody, sc-73597 (Santa Cruz Biotechnology,
Heidelberg, Germany) raised against factor VIII of human
origin, with epitope mapping to the A2 domain residues
497–510 and 584–593 was used in experiments investigating
FVIII activation by thrombin. The membranes were then incu-
batedwith the secondary antibody, HRP-linked antimouse IgG
NA931 (GE Healthcare, New Jersey, United States).
Activation of FVIII by Thrombin: Functional Assays
For thrombin activation, recombinant FVIII samples were
reconstituted at a concentration of 100 IU/dL (ffi 20 µg/mL
ffi 70 nM) into 50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
2.5 mM CaCl2, 5% glycerol and incubated at 25°C with
20 nMhumanα-thrombin.14At timed intervals (0.5–20min-
ute), samples were taken from the mixture, and the activa-
tion was terminated by hirudin (20 nM, purchased from
Sigma-Aldrich, units/mL) and diluted appropriately for FVIIIa
activity determinations. 10 µL of these samples were diluted
in 990 µL of human FVIII-deficient plasma from Werfen
(Milano, Italy) and assayed for FVIII activity by the two-stage
chromogenic assay, as described above. The presence of very
low thrombin and hirudin concentration in the final solution
did not affect the activation of FX.
Since the kinetic curves for the activation of the various
FVIII products showed bell-shaped profiles, we analyzed the
experimental data using a simplified kinetic scheme:
corresponding to:
In the kinetic scheme 1a, B represents the concentration of
activated FVIIIa associated with the formation of FXa at any
time of the reaction, whereas C reflected the inactivation of
FVIIIa at any time.15 The analysis of the generation of FVIIIa
curves in these studies was based on the following phenom-
enological approach. In the activation phase, no attempt was
made to use a model with any mechanistic connotation; only
an empirical description was accomplished. Although it is
known that FVIII activation by thrombin could be described
at least minimally by Michaelis–Menten kinetics, analytical
integration of the Michaelis–Menten function is impossible.
Thus, although calculated by this simplified scheme, the over-
all time course of generation of FVIIIa at any time, [FVIIIa]t, is
given by the following exponential equation:
where [FVIIIa]max is the final zymogen FVIII activated and k1
and k2 are pseudo-first order rate constants.
FVIII Activity Assays
FVIII activity was determined by different methods:
• One-stage clotting assay: The assayswere performed on an
automated coagulation instrument (Top 700, Instrumen-
tation Laboratory, Milano, Italy). The standard FVIII cali-
bration curve was prepared with the Normal Plasma
Calibrator from Werfen. This procedure was used for all
products but Refacto AF, whose concentration was mea-
sured with the two-stage chromogenic assay alone (see
below). Before determination, the sampleswere diluted at
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least 2,000-fold to concentrations that fall within the
linear range of the FVIII calibration curve. Each sample
was analyzed in duplicate, and the results were averaged.
• Two-stage chromogenic FVIII activity: FVIII chromogenic
assay detection kits were purchased from Chromogenix
(Werfen Group, Milano, Italy). The activity of generated
FXa was measured at 405 nm, using the S2765 chromo-
genic substrate and a Top 700 instrument.
FVIII Antigen Assay
FVIII antigen levels were measured using the commercial Kit
ASSERACHROM FVIII:Ag (STAGO, Asnieres-sur-Seine,
France). Control plasma (100 VIII:Ag IU/dL by comparing
with the International Standard) was used as the reference.
The assay sensitivity was 0.1 IU/dL FVIII:Ag.
Assay to Measure Total Albumin Concentration
Albumin content of Kogenate was determined by an auto-
mated immunoassay (Hitachi 704/Roche Albumin Reagent).
Results
UV Spectra of Recombinant Products
Themain characteristics of the recombinant FVIII formulations
used in this study are listed in ►Table 1. All the recombinant
products showed typical protein absorbance peaks at 280
 1 nmattributable to tryptophan and tyrosine residues and a
modest shoulder at 288 nm arising from tryptophan’s con-
tribution alone, as shown in ►Fig. 1. The spectra were not
significantly affected by Tween 20 and polysorbate 80, present
as stabilizers in the Advate, Kogenate, and Refacto AF prepara-
tions. Genuine Tween 20, polysorbate 80, PEG 3350, and
threalose at the final concentration of 0.1 mg/mL, 0.2 mg/mL,
3 mg/mL, and 2 gr/dL, respectively, showed an absorbance at
280 nm ranging from0.003 to 0.008 AU, respectively. Based on
the absorbance at 280 nm, the FVIII concentration of Advate
and Refactowas calculated to be 0.66  0.07 and 0.497  0.06
mg/mL, respectively. It must be reminded that the protein
contentofKogenate at 280 nmconcerning FVIII per sewasonly
Table 1 Main characteristics of the three recombinant Factor VIII products used in the study
Characteristic Advate Kogenate Refacto AF
Name of marketing
authorization holder
Baxalta/Shire Bayer Pfizer Limited
Generation Third Second Third
Engineered cell line CHO
(Chinese hamster ovary)
Baby hamster kidney (BHK) CHO
(Chinese hamster ovary)
Co-expression of VWF
in engineered cell line
þ  
Primary sequence Full length Full length B-domain deleted
Molecular weight 275 kDa 275 kDa 170 kDa
Virucidal treatment Solvent/detergent Solvent/detergent Solvent/detergent,
nanofiltration
Purification process Ion exchange chromatography,
monoclonal antibody
immunoaffinity chromatography
Ion exchange chromatography,
monoclonal antibody
immunoaffinity chromatography
Immunoaffinity
chromatography
Stabilizers and
excipients
• Tris (hydroxymethyl)
aminomethane
• Calcium chloride
• Mannitol
• NaCl
• α,α-Threalose
• Histidine
• Glutathion (reduced)
• Polysorbate 80
• Sucrose
• Calcium chloride
• NaCl
• Histidine
• Glycine
• Polysorbate 80
• Imidazole, tri-n-butyl,
phosphate, and copper
• Sucrose
• Calcium chloride dihydrate
• L-Histidine
• Polysorbate 80
• Sodium chloride
Abbreviations: VWF, von Willebrand factor.
Fig. 1 UV absorbance spectra of recombinant FVIII products: Advate,
Kogenate, and Refacto were reconstituted in sterile water for the
therapeutic injection, and absorbance spectra were obtained at 0.1-nm
intervals in a thermostatic (25°C) 1-cm-pathlength cuvette lodged in a
cell holder of an Agilent Cary 60 spectrophotometer. Each product was
reconstituted with sterile water for injection at a nominal concentration
of 3,000 IU/mL. A: Advate; R: Refacto; K: Kogenate.
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apparent (0.84  0.2mg/mL) due to thepresence ofalbumin in
the solution. The above-reported FVIII concentrations were
similar (except for Kogenate) to those measured by ELISA:
Advate and Refacto AF showed a concentration of 0.58  0.09
and 0.39  0.04 mg/mL, respectively, while the Kogenate con-
centration was equal to 0.55  0.06 mg/mL.
SE-HPLC of the Recombinant FVIII Concentrates
The chromatographic analysis of the recombinant FVIII con-
centrates by SE-HPLC showed in all products the presence of
significant amounts of very high molecular weight proteins,
which were eluted in the void volume, which contained any
protein with m.w. >500 kDa (►Fig. 2A). This finding was
particularlyevident inKogenate.Notably, in all cases, afiltering
procedure throughMillex-GP 220 nmfilters eliminates almost
completely the aggregated proteins (►Fig. 2B). We tried
unsuccessfully to quantify with precision the relative amount
and molecular weight of the aggregated/unfolded material in
the recombinant FVIII formulationsby SE-HPLC.Unfortunately,
this aggregated/unfolded proteinaceousmaterialwas eluted in
the void volume (containing proteins with m.w. >500 kDa) so
that the cumulative peak did not allow a precise and reliable
calculation of the molecular weight of the proteins (►Fig. 2A).
Activation of FVIII Products by Thrombin:
Electrophoretic Studies
Proteolysis of FVIII by thrombin was successfully monitored
by Western blotting using a MoAb mapping of an epitope
contained in the A2 domain of FVIII. Under the experimental
conditions used in these experiments, thrombin hydrolyzed
the entire amount of the A2 domain of Advate generating a
fragment of50 kDa approximately 15minutes after throm-
bin addition, as shown in ►Fig. 3. A similar pattern was
observed for Recombinate (not shown) which derives from
the same cell type (CHO) and the same gene construct,
although it is a first-generation product and contains sig-
nificant amounts of human albumin, which renders less clear
the final gel of the Western blot. The other recombinant
products (Kogenate and Refacto) were efficiently proteo-
lyzed by thrombin, although after 15minutes a little amount
of the native A2 domain was still present (►Fig. 3). The A2
band was still present even after 180 minutes since the start
of the thrombin addition (data not shown).
Dynamic Light Scattering
To better characterize the properties of the recombinant
FVIII products (Advate, Recombinate, Kogenate, and Refacto
AF), we also performed DLS measurements. It must be
reminded that Recombinate contains human albumin in
the final preparation at a concentration of 0.4 mg/mL at a
nominal FVIII concentration ¼ 100 IU/mL. The concentration
range of FVIII preparations used in the DLS experiments
(100–250 IU/mL) was chosen to reflect realistic concentra-
tions of FVIII solution obtained upon reconstitution of the
powders commercially available for the pharmaceutical
preparations. The profiles of the autocorrelation function,
G(t), for each FVIII product (data not shown) used in DLS
experiments suggested the presence of polydisperse
Fig. 2 (A) SE-HPLC of Advate (400 IU/mL) eluted with 20 mM
phosphate buffer, 0.15 m NaCl, pH 7.40; (B) SE-HPLC of Kogenate (400
IU/mL) before (purple line) and after (black line) passage through a
Millex-GP 220 nm filter (Merck). Note the almost complete elimina-
tion of the aggregated proteins after filtering the solution of
Kogenate. The same result was obtained with Advate and Refacto AF.
The molecular weight markers (250 and 150 kDa) and the void volume
(protein material with m.w. > 1,000 kDa) are indicated by the arrows.
SE-HPLC, size exclusion high-performance liquid chromatography.
Fig. 3 Thrombin-catalyzed activation of recombinant FVIII contained
in Advate (A), Kogenate (K), and Refacto AF (R). The experimental
conditions are reported in the Methods section. The detection of the
A2 domain was accomplished by the MoAb sc-73597. Thrombin was
used at a concentration of 2.5 nM, and the hydrolysis products were
analyzed after 180-minute reaction.
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systems.7 This result obliged to apply the multiple decay
analysis (CONTIN) to determine the hydrodynamic radius of
the molecules in solution. From the hydrodynamic radius
and shape factors, it is possible to establish the size of the
particle.7 Size information is extracted from the measured
correlogram by exponential fitting, where the particle diffu-
sion coefficient D is proportional to the lifetime of the
autocorrelation curve according to the following expression:
G(t) ¼ B þ Σ A·exp(2·q^2·D·t) (where B is the baseline, A is the
amplitude, and q is the angle and wavelength dependent
scattering vector). The hydrodynamic radius is then calcu-
lated from the diffusion coefficient using the Stokes–Einstein
equation.10 A theoretical hydrodynamic radius of 7 and
15 nm is expected for a globular and a linear molecule
model, respectively, considering a molecular weight of 275
kDa for monomeric full-length FVIII molecules. In each
preparation, at least two groups of components were iden-
tified: the first, with a hydrodynamic radius spanning from 7
to 30 nm, could be tentatively attributed to FVIII in a mono-
and oligomeric form,while the second, spanning from50 to
1,000 nm likely reflected the existence of unstable aggre-
gates, partially unfolded or high molecular weight forms of
FVIII. The second group of components peaking at >100 nm
present in each preparation, and particularly in Kogenate,
entirely disappeared after passage through filters with
220 nm cutoff. The range of the nominal concentration of
rec-FVIII products used in these experiments would corre-
spond to approximately 20 to 50 µg/mL (assuming a FVIII-
specific activity of 5,000 IU/mg). Thus, at these nominal
concentrations and assuming a molecular mass of 275 kDa
for full-length FVIII, the monomeric recombinant products
could provide a backward DLS intensity signal very low or
virtually absent in a Zetasizer Nano S instrument. The fact
that we obtained significant DLS signals pertaining to objects
with dimensions much higher than expected for FVIII mole-
cules (up to 600 nm of hydrodynamic radius) represents a
proof that protein aggregates are present in the pharmaceu-
tical solutions. It is essential to keep in mind that there is a
very strong dependence of the intensity of light scattered,
with respect to particle diameter. These two values have a
sixth-power relationship, which means, for example, that a
100-nm particle scatters onemillion times as much light as a
10-nm particle. Moreover, the signal pertaining to objects
with very high hydrodynamic diameter could not derive
from the excipient/stabilizers present in the pharmaceutical
preparations. Genuine excipients such as polysorbate 80,
Tween 20, or mannitol at the same concentrations present
in the preparations (polysorbate 80: 50–200 µg/mL; manni-
tol 8% [w:v]) did not produce in fact any significant signal in
the DLS apparatus pertaining to particles with diameter
>1 nm (►Fig. 4A). This result resembled what was observed
in SE-HPLC experiments where, after a passage of rec-FVIII
products through filters with a cutoff of 220 nm, the very
high m.w. proteins were eliminated.
Two-Stage Chromogenic Assay of Recombinant FVIII
Products
The possible formation of high-grade FVIII aggregates that
could affect the activity of FVIII was further explored by a
functional assay, where the FX activating ability of each FVIII
product, measured by a two-stage chromogenic assay, was
investigated and compared with the nominal FVIII activity
certified by the manufacturers. To do that, four recombinant
FVIII concentrates were studied over a concentration range
spanning from 9.4 to 300 IU/dL. The 13th British Standard for
Blood Coagulation Factor VIII Concentrate was used as the
reference (code labeled 10/188). In all cases, for sampleswith
nominal FVIII concentrations>150 IU/dL, appropriated dilu-
tions were performed to measure FVIII levels falling in the
linear portion of the calibration curve. The final concentra-
tionwas calculated considering the dilution factor. As shown
Fig. 4 DLS measurements on rec-FVIII preparations and solution of
genuine excipients and stabilizers present in the therapeutic pre-
parations. All samples were equilibrated for 300 seconds. at 25°C just
before the measurements start. The figure shows a size distribution of
the particles by intensity measurements. (A) The distributions of the
intensity of light scattered as a function of the diameter of Tween 20
(genuine solution: 0.2 mg/mL) and mannitol (genuine solution: 8%).
Note the absence of particles with a higher hydrodynamic diameter.
(B) Overlapping of the lines concerning the distribution of the
intensity as a function of the diameter of the particles present in the
Advate, Refacto AF, and Kogenate solutions. The large aggregates
(indicated by a brace parenthesis) were removed by filtration on a
membrane with a pore diameter of 220 nm (continuous line), while
particles with d < 100 nmwere not altered by filtration. DLS, dynamic
light scattering.
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in ►Fig. 5, Advate and Recombinate showed a good corre-
spondence between the nominal and measured functional
activity over the entire concentration range explored, while
the other two products (Refacto AF and Kogenate) showed a
progressive reduction of the measured activity compared
with the nominal concentration. The intra-assay standard
deviation of the measured activity of these products
increased as a function of their concentration, especially
for Kogenate and Refacto (►Fig. 5). Overall, the findings
described above strongly suggest that the occurrence of
aggregation processes, randomly developing as a function
of the product concentration, could be responsible for the
observed discrepancy between the measured and nominal
FVIII activity.
Activation of FVIII by Thrombin
The kinetic experiments aimed at investigating the ability of
thrombin to activate the various FVIII preparations were
analyzed by Eq. 2, whose best-fit parameters are listed
in ►Table 2 and shown in ►Fig. 6. Under the experimental
conditions used in this study, the maximum FVIIIa genera-
tion peaked between 0.5 and 1 minute, with the rate of
activationmuch higher than the inactivation rate (►Table 2).
The activation rates showed moderate but significant inter-
species differences with pseudo-first order activation rate in
the order: Advate > Recombinate > Refacto ¼ Kogenate.
The inactivation rate constants were not significantly differ-
ent among the different products, as shown in ►Table 1.
Discussion
In the present study, we investigated some basic biochemical
and biophysical properties of three commercially available
rec-FVIII concentrates. Both SE-HPLC and DLS findings
showed that these marketed rec-FVIII products, reconsti-
tuted following the procedures indicated by the producing
companies, contain various amounts of aggregated FVIII
molecules. These particles show significantly different
hydrodynamic diameters, ranging from 100 to 1,000 nm.
These solutes, too large to be attributed to monodisperse
FVIII molecules, are removable with 220 nm cutoff filters
and likely reflect the presence of unstable aggregates and/or
partially unfolded forms. Whether the formation of these
aggregates randomly depends on either the production and
storage conditions of each lot or themethod of reconstitution
Fig. 6 FVIIIa activation by thrombin of Advate, Recombinate,
Kogenate, and Refacto AF. The continuous lines were drawn using the
best-fit parameters [FVIII]max, k1, and k2 of Eq. 2 listed in ►Table 2. In
all cases, FVIII preparations were used at 100 IU/dL and thrombin at
20 nM. Experiments were performed in duplicate using different lots
of the products (SD: 6  2%), and average values are shown. SD,
standard deviation.
Fig. 5 Difference between the nominal FVIII concentration of the
products used in this study (x-axis) and the corresponding concen-
tration (y-axis) measured with a chromogenic assay. The values are the
mean of three different lots of each product. The vertical bars
represent the standard errors from three different measurements
from three different lots of the product. The intraassay standard error
was 8  3%.
Table 2 Best-fit kinetic rate constants derived from the application of Eq. 2 for FX activation by thrombin-activated FVIII from
Advate, Recombinate, Kogenate, and Refacto AF
Parameter Advate Recombinate Kogenate Refacto AF
[FVIIIa]max (IU/mL) 108  17 103  17 100  15 103  15
k1 (min
1) 1.41  0.62 1.27  0.6 0.85  0.3 1.07  0.4
k2 (min
1) 0.05  0.02 0.06  0.02 0.07  0.02 0.049  0.016
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is unknown. In DLS experiments a significant inter-lot varia-
bility (10–15%) in the amounts of these large aggregates was
observed. Notably, the presence of FVIII aggregates has been
recently found using analytical ultracentrifugation in Advate,
Helixate, and Kogenate.16 Notably, in the present study,
Advate was the only product in which it was possible to
identify a more definite pattern of monodisperse forms of
FVIII molecules (►Fig. 4). This behavior may derive from the
specific conditions used to express the protein in CHO cells,
in which Von Willebrand Factor (VWF) is co-expressed with
the rec-FVIII to stabilize the latter. This strategy could favor
the attainment of a correct conformation of FVIII, exploiting
chaperon-like functions of VWF that would counteract
unfolding and aggregation processes of FVIII molecules. A
lower presence of protein aggregates in the Advate formula-
tion was also found in sedimentation velocity analytical
ultracentrifugation measures, as recently reported.16
The above findings raised the question as to the presence
of FVIII components with a very high hydrodynamic size
could even affect the functional properties of the rec-FVIII
concentrates. The activity of the various FVIII products was
significantly altered as a function of the factor concentration.
This finding agrees with the hypothesis that, being the
formation of molecular macroaggregates a bimolecular pro-
cess, it directly depends on the concentration of the reac-
tants. Furthermore, the kinetics of protein aggregation may
be an order ofmagnitude faster than folding kinetics, causing
a significant fraction of the protein to be inactivated/una-
vailable.17 Therefore, the process of protein aggregation may
even favor a partial loss of their biochemical activity, as
experimentally shown. According to the lower presence of
aggregated particles, Advate (and its progenitor Recombi-
nate) did not show a significant divergence of the FX activat-
ing capacity as a function of its nominal concentration. At
variance with Advate, the other recombinant products
Kogenate and Refacto partially lost their activity progres-
sively as a function of their concentration, reaching a detri-
mental reduction of activity at 150 IU/dL nominal
concentration. Moreover, the presence of molecular aggre-
gates affected also the kinetics of FVIII activation by throm-
bin, as shown in►Fig. 5. In these experiments, Advate, which
contained the lowest amount of aggregated particles,
showed the best kinetic profile with the highest pseudo-first
order rate constant of its activation by thrombin. The pre-
sence of aggregates or denatured protein in recombinant
FVIII formulations has been also hypothesized to favor the
production of anti-FVIII antibodies.16,18 The presence of this
irreversibly aggregated material could explain, besides other
well-known risk factors,17,19–21 the higher prevalence of
inhibitor formation in patients treated with recombinant
FVIII preparations, especially the second-generation pro-
ducts.6,7 Furthermore, the immunogenicity of protein aggre-
gates increases as a function of their molecular mass.22,23 It
was speculated that the molecular aggregates of FVIII might
have a defective binding to VWF and be more easily detected
by the antigen-presenting cells that induce an immunologi-
cal response with the production of inhibitors.9,24 As
remarked above, Advate showed a relatively lower content
of protein aggregates compared with Kogenate and Refacto
and this fact might contribute to explain the lower incidence
of inhibitor formation inpatients treatedwith this product as
compared with Kogenate and Refacto, as suggested in early
and more recent observational studies.6,7,25,26 In addition,
the results of this study outline also the risk that the
reconstitution of the recombinant products at a relatively
high concentration may affect their pharmacodynamics/
pharmacokinetics, limiting in part the availability of func-
tional FVIII molecules. The introduction in the clinical prac-
tice of new recombinant FVIII products, also including the
extended-half-life (EHL) formulations, currently represents a
useful opportunity to investigate their physicochemical
properties concerning the presence of molecular aggregates,
in relation to the results that will be obtained on previously
untreated patients (PUPs) in RCTs. Thus, it seems timely to
investigate these properties of both EHL and modified pre-
parations of rec-FVIII. It could also be very intriguing to
compare the presence of molecular aggregates in plasma-
derived FVIII preparations, although the presence of high
molecular weight VWF multimers in these pharmaceutical
formulations renders experimentally impossible any
attempt to unequivocally verify this point.
In conclusion, the combined use of SE-HPLC, DLS, and
enzymatic assays showed that aggregates with very high
molecular size are present in therapeutic preparations of rec-
FVIII and affect their functional properties. Thus, the possible
formation of large-size aggregates in rec-FVIII products,
particularly in the second-generation products, should not
be ignored as a source of both altered pharmacodynamics/
pharmacokinetics and as a possible trigger of an immune
response in PUPs.
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